Skip to content

Acupoint Combination for the Prevention of PONV in High-Risk Patients Undergoing Painless Gastrointestinal Endoscopy: A Randomized Controlled Study

Acupoint Combination for the Prevention of PONV in High-Risk Patients Undergoing Painless Gastrointestinal Endoscopy: A Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120720
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-03-18
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PONV

Interventions

TEAS group:The TEAS group received transcutaneous electrical acupoint stimulation (TEAS) at bilateral PC6, LI4, and ST36 acupoints starting 30 minutes before anesthesia induction until the end of the
Control group:Group C only received acupoint localization and electrode patch application at bilateral PC6, LI4, and ST36 acupoints, connected to a pulse electrotherapy instrument, but no electrical s

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Voluntary participation in this study with signed informed consent; 2.Age 18-65 years, body mass index (BMI) 18-30 kg/m^2, ASA physical status I-III; 3.Apfel risk score of 3 points (i.e., meeting the following three criteria: female gender, history of PONV or motion sickness, non-smoker); 4.Scheduled for painless gastrointestinal endoscopy.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women, or those with pregnancy plans within 3 months; 2.Contraindications or allergic reactions to benzodiazepines or opioid drugs; 3.Previous history of transcutaneous electrical acupoint stimulation, or contraindications to transcutaneous electrical stimulation, including local skin damage or infection at the stimulation site, or presence of implanted electrophysiological devices; 4.Preoperative significant respiratory or circulatory dysfunction, as well as hepatic or renal insufficiency; 5.Communication barriers, including language barriers, history of neurological diseases, or psychiatric disorders; 6.Participation in other clinical trials within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting at 24 hours postoperatively;Patient satisfaction score;

Secondary

MeasureTime frame
Incidence of nausea and vomiting at 30 minutes and 6 hours postoperatively;Severity of nausea and vomiting at 30 minutes, 6 hours, and 24 hours postoperatively;Quality of recovery from anesthesia at 24 hours postoperatively;

Countries

China

Contacts

Public ContactXing Na

The First Affiliated Hospital of Zhengzhou University

fccxingn@zzu.edu.cn+86 139 4909 5172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026